TP53 and neoplasm: Furthermore, the identification of additional markers such as TP53 mutations, loss of chromosome 22q, C11, or f95-RELA fusion, and c-Myc amplification offers significant insights into the tumor's characteristics, progression, and potential therapeutic targets [23].